QDIS Blog

A blog about chemistry, drug development, science, and technology

Pages (999999): [1] 2 3 » ... Last »

January 17, 2008

E.U. raids Major Drug Companies

by @ 4:00 pm.  Filed under Pharma News

Wow! I read today that the EU performed raids on almost all the major drug companies on Wednesday. This includes Pfizer, Sanofi-Aventis, GlaxoSmithhKline, Astrazeneca, Merck, and Johnson & Johnson.

E.U. raids drug companies in broad inquiry

The authorities are looking for evidence of abuse of patents and illegal deals to keep cheaper generics off the market. Here is a quote form the article.

The raids will help establish if companies created barriers to competitors, whether they misused patent rights or engaged in “vexatious litigation” and if some firms abused their dominance of the market.

It will be interesting to see what comes of this if anything. I’ll but we don’t hear anything else about this for months but I’ll certainly be keeping my eyes open for further information.
Technorati Tags: , , , ,
meilleurs casino en lignejeu roulette russebaccarat frjeu slots casino en lignebonus de casino en lignepaysafecard casino bonuswww casino de pariscasino machine a sous gratuitsla règle jeu roulettewww casino gratuitesjeu la rouletteslots onlinecasino partouchewww geant casinovideo poker gratuitesjeu casino virtueljeux de casino gratuitescasino en eurojeu de hasardjeux casino poker gratuitescasino games pro 2007casino bonus 100casino en ligne frliste jeux casinomeilleurs jeux de casinojeux casino enfantle casinogéant casinos en lignepoker les reglespoker en ligne francaisgagner poker onlinele meilleur poker en ligneworld championship pokertelecharger party pokerjouez au poker en lignetexas holdem en ligne gratuitespoker 3dpoker en ligne debutantapprendre jouer au pokerjeux poker a telechargerjouer poker virtuelpoker hold hem gratuitesjouer au pokerjeu online poker tourtelecharger de pokerlogiciel pokerjeux video.compoker le jeujeux de poker en lignejouer au poker gratuitement

Email Ed Vawter



Related Posts:
  • Outsourcing No Longer Optional?!
  • Another biotech merger albeit a smaller one
  • My thoughts on Google Buying YouTube
  • More Merger Mania Ahead For Pharma
  • Drug Safety Data from Clinical Trials

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    January 15, 2008

    Nova episode “Conquest of Cold”

    by @ 2:53 pm.  Filed under Science

    As you may have noticed I’ve had some time to get caught up on programs I tivo’ed. Another program I really enjoyed was Nova’s “Absolute Zero: The Conquest of Cold” which you can watch online for free.

    I’ve always been a big fan of Nova and it is on my season pass on my tivo. My only disappointment was how it ended and I won’t ruin it for anyone who hasn’t seen it but thought they could have done more. Then I find out there is going to be another follow on called “Absolute Zero: The Race for Absolute Zero”. I’m hoping my disappointment will be cured with this next episode. It is set to air on Jan 15 at 8 pm at least according to the PBS website.

    I highly recommend this Nova episode for anyone with even a passing interest in science. They did an excellent job of covering the history of the study of cold and even though I’ve been a life long scientists, I still learned something, especially about the first use of “air conditioning”.

    I am constantly amazed at how little knowledge some of my fellow scientist have of the history of science Many do not seem to be at all interested in the historical aspects of science but I think you can learn a lot about science itself and how it interfaces with society by understanding where we come from. A great example of the history of science not being taught in the area of chemistry (my special area of interest) is the program “Forgotten Genius - Percy Julian“. Although I have taken a course on the history of chemistry and read a couple of books about the history of chemistry and had never heard of Percy Julian. You can also view this program online for free and read a lot of other information on this black chemist and his accomplishments.

    I always enjoy these sort of science and history related shows and this reminds me a lot of the Connections series with James Burke that the BBC did several years ago. I really wish TLC of Discover would re-air those episodes. You can still get them on DVD but they are expensive; $149 for 5 DVD ten programs. Connections 2 is also available for the same cost but it doesn’t look like Connections 3 is available.

    Technorati Tags:

    Email Ed Vawter



    Related Posts:
  • Nova ScienceNow Segment on Bird Flu
  • FDA Scrutinizing Kids’ OTC Cold Remedies
  • Searching the Internet Episode 2
  • Phenylephrine reformulation a flop?
  • Your Vote on Nov 7 is Important

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    PBS Frontline: The Medicated Child

    by @ 2:22 pm.  Filed under Health News, Pharma News

    I Tivo’ed Frontline’s “The Medicated Child” recently and finally got around to watching it the other night. This is a follow up from an episode they did on this back in 2001. You can watch and read about it online. It was somewhat disturbing at parts especially when they mentioned a young child who was on several atypical anti-psychotics at the age of four! Here are some of the interesting points brought up:

    1. There has been a 4,000% increase in diagnosis of psychiatric problems in young children over the last ten years

    2. Although doctors do not agree about bipolar in young children many kids are being diagnosed as being bipolar at ages as young as four years old.

    3. There is a growing number of strip mall places offering “brain scans” looking at blood flow to the brain to give a diagnosis. The company featured was co-founded by a social worker and she was the one featured giving the family the diagnosis of the problem. To me this edges on the verge of giving medical advice but not being a medical doctor.

    4. In one case they highlighted it was teachers who told the parents their child had ADHD. I know teachers and I do not envy their job but I think suggesting an actual diagnosis is inappropriate.

    5. Another big problem mentioned only in passing on the program was that many of these children are being treated by family pediatricians and not by child psychiatrists.

    I’m not always a fan of highlighting individual cases which may or may not be typical. However, these do pull on our heart strings and it does highlight how desperate these families become when dealing with “the problem child”. I truly feel for these parents who are trying everything to help their child but nothing seems to work. Just take a look at the discussion page and read what some of these folks have gone through. This situation is what leads to some of these snake oil salesmen mentioned in point 3 above.

    Part of the problem is the whole quick fix attitude especially in the US and the resulting expectation (re-inforced by the pharmaceutical industry) that a few pills can solve all your problems. I have always believed that in the case of mental issues that medication and therapy together are much more beneficial than drugs along.

    I really liked the program and highly recommend it. You can watch it for free online and they also have lot of information and further interviews with experts here. There is also a Parents Guide.

    I personally look forward to the day when we can run a blood test or do a brain scan and come up with a definitive diagnosis and be able to confidently prescribe medications that will solve the problem >90% of the time. Unfortunately, I don’t know if this will occur in my lifetime. This is one situation where I truly hope I am wrong.

    Technorati Tags:

    Email Ed Vawter



    Related Posts:
  • ViroPharma, the FDA and Easing Generic Rules

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Spending on marketing vs R&D

    by @ 12:17 pm.  Filed under Pharma

    The subject of pharma spending on R&D versus Marketing is one that comes up frequently. Recently FierceBiotech has had an article on this.

    Drug industry spends nearly twice as much on marketing than on research and development - FierceBiotech - Biotechnology Articles, Biotech Industry News, FDA Approval News:

    Here is the link to the PLoS Medicine journal they refer to.

    PLoS Medicine - The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States

    It makes for some interesting reading. I personally think that there tends to be a discussion more on what should or should not be included as “marketing expenses” and the big picture tends to get overlooked. Maybe this is the tactic that is being used to avoid talking about the real issue.

    The article does a good job I feel of at least explaining how they came up with their numbers. I’m sure there will be debate on what they decided to include and some of their assumptions but the very fact that it confirms the suspicions of the public will mean it will be readily accepted.

    Their figure is $57.5 billion spent on promotion or 24.4% of every dollar versus $31.5 billion for R&D or 13.4%. THis means there is almost twice as much (1.8 actually) spent on promotion over R&D.

    Here is the conclusion from that article.

    From this new estimate, it appears that pharmaceutical companies spend almost twice as much on promotion as they do on R&D. These numbers clearly show how promotion predominates over R&D in the pharmaceutical industry, contrary to the industry’s claim. While the amount spent on promotion is not in itself a confirmation of Kefauver’s depiction of the pharmaceutical industry, it confirms the public image of a marketing-driven industry and provides an important argument to petition in favor of transforming the workings of the industry in the direction of more research and less promotion.

    The article make the point that according to their figures the industry spends twice as much on promotion as it does on R&D. This will be controversial since it is counter to the common claim made by the pharmaceutical industry and confirms some of the perceptions of the man on the street.

    I personally feel and have stated here several times that the industry as a whole does not seem to take seriously the perceptions on the street and the industry’s very actions taken to counter some of these perceptions only serves to reinforce some of those negative images out there. The industry seems to forget that perception matters and can be very damaging.

    Technorati Tags: ,

    Email Ed Vawter



    Related Posts:
  • Pfizer to Cut 2,200 Marketing Jobs
  • 2007 to Be a Tumultuous Year for Healthcare Especially Biotech and Pharma
  • Online Pharmaceutical Spending to Reach $1.3 Billion by 2008
  • Gilead in Trouble over HIV Drug Marketing
  • Dr. Jarvik, Lipitor and Ethics

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    January 10, 2008

    Dr. Jarvik, Lipitor and Ethics

    by @ 12:49 pm.  Filed under Pharma

    This is the kind of stuff that gives the pharma industry a bad name. I’ve long had a problem with some of those on the marketing side who see

    Congress questions Jarvik’s Lipitor lip service, credentials as part of celebrity-pitch probe - International
    Herald Tribune
    :

    I think the pharma industry needs to think about the “ethical” part of the name ethical pharmaceuticals, a term that isn’t used much anymore (maybe for good reason). I personally feel too many large pharma marketing departments are run by “soap and toothpaste” marketers who don’t understand (or don’t want to understand) the impact of what they are putting out there in terms of advertisements.

    I feel there is too much emphasis on stretching the envelope of what is permissible and try to see what they can get away with and not enough focus on the perception of the drug industry in the eyes of the person on the street.

    Email Ed Vawter



    Related Posts:
  • More Companies Approved to Sell Generic Zocor (simvastatin)

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Drug Approvals in 2007

    by @ 11:27 am.  Filed under FDA

    Here are a couple of good blog postings about the low number of drug approvals in 2007.

    The IN VIVO Blog: Another Dismal Year for New Drug Approvals:

    Where have all the new drug’s gone: Industry’s medicine cabinet running empty on compounds- NJ.com

    With only 18 approvals it is the lowest since 1983 when there were only 14. The FDA says final figures won’t come out until March but even then most of us think the total will likely not be any higher than 19. While there seem to be a lot of theories as to why this is the case, I don’t think there is any one singular explanation. I personally think it is a combination of the FDA being more cautious (although the FDA denies this and says there has been no policy change) and the fact that all the low lying fruit has been picked and it is indeed much harder now to find new and innovative therapies.

    I do believe that some of the recent breakthroughs in basic research such as the human genome will eventually lead to new drug discoveries but that one of the primary issues is everyone under estimates how long it takes to go from basic research to commercial application, especially in the drug industry. This is one of the primary mind traps that everyone falls into in all industries but it seems to be exaggerated in the pharmaceutical industry.

    I’m not sure what will help the situation and I’m not confident it will turn around soon. I am confident that in the long run, the issue will be resolved. I just hope it doesn’t take too long.

    Technorati Tags: ,

    Email Ed Vawter



    Related Posts:
  • Is the FDA Approving More Drugs?
  • The FDA and 2008
  • Drugmakers to Pay FDA to Check TV Ads
  • FDA Approves Eli Lilly’s Cymbalta for Generalized Anxiety Disorder
  • Any interest in a pharmaceutical news podcast?

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    January 2, 2008

    PharmaLive: Pfizer Receives Approvable Letter from FDA for Dalbavancin

    by @ 10:08 pm.  Filed under FDA, Pharma News

    Here is the first of what I am sure will be plenty of approvable letter from the FDA this year. Pfizer received an approvable letter for dalbavancin, a once weekly two dose antibiotic useful for methicillin resistant bacteria. Note that this drug came to Pfizer by way of their acquisition of Vicuron.

    PharmaLive: Pfizer Receives Approvable Letter from FDA for Dalbavancin :

    Basically the FDA wants more evidence regarding non-inferiority as the basis for approval.

    I personally think that antibiotics is NOT an area where the FDA needs to be seen as holding things up. With the rising number of MRSA infections occurring even outside the hospital the need for new antibiotics is growing and will continue to grow. Having been affected by this personally and knowing that only vancamycin worked in that case the need for new antibiotics will continue to be of concern.

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • Neurocrine Receives Good and Bad News for indiplon Capsules and Tablets
  • First OTC Diet Drug Receives Approvable Letter And Other Diet Drugs In Development
  • Rimonabant and Type 2 Diabetes
  • Neurocrine and Pfizer End Agreement for Indiplon
  • FDA Issues Third Approvable Letter to Encysive for Thelin

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    The FDA and 2008

    by @ 9:55 pm.  Filed under FDA

    It will be interesting to see how things develop with regards to new drug approvals and the FDA in 2008.
    My guess is that for new drugs for which treatment already exists that the FDA will continue to demand evidence of not only of safety and effectiveness but also that is is an improvement over the currently available treatments. This seems to be shared by Fierce Biotech.

    The FDA: Caught between a rock and a hard place - FierceBiotech

    I can understand the FDA reacting to recent situations such as Vioxx but they do indeed seem to be sending a mixed message; emphasizing the need for speeding drugs to market but then seeming to have set a higher standard. THe FDA says therre jave been no policy changes but the fact that only 15 new drugs were approved in 2007 seems to indicate otherwise.

    I just hope that we can have a open and honest discussion about risk management and acknowledge that all drugs have risk and many times that full impact of that will not be determined until after the drug has gone on the market.

    Technorati Tags: ,

    Email Ed Vawter



    Related Posts:
  • Online Pharmaceutical Spending to Reach $1.3 Billion by 2008
  • President Seeks $78 Billion Cut on Healthcare Over Five Years
  • Dr. Jarvik, Lipitor and Ethics
  • CDC Recommends Gardasil vaccination
  • Dendreon will delay Provenge, cuts jobs

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    October 4, 2007

    Review of Important Items from Sept 17-30

    by @ 8:00 am.  Filed under FDA, Pharma News, Pharma

    Here are a few of the important articles from the last couple of weeks.

    Glaxo set to axe staff as crisis hits drug - Telegraph
    Generic Biotech Drugs Won’t Be in U.S. Legislation Bloomberg.com: News
    The Scientist : New patent rules hurt biotech?
    Chemical & Engineering News: Government & Policy - Patent Reform Inches Ahead
    AstraZeneca to outsource manufacturing - Times Online
    AstraZeneca To Outsource Drug Manufacturing - Contract Pharma
    StockHouse.com : Encysive Pharmaceuticals Receives Written Response From FDA On
    Cephalon warns over pain drug deaths| Reuters
    PharmaLive: Adverse Drug Events Reported to FDA Appear to Have Increased Markedly
    Sanofi-Aventis Developing New Drugs: Financial News - Yahoo!
    Finance

    House Passes Bill to Improve Drug Safety: Financial News - Yahoo!
    Finance

    Senate OKs FDA drug safety bill - washingtonpost.com
    Many drugs slip through regulatory ‘black hole’ - CNN.com
    Bristol-Myers to buy partner Adnexus for $430 million”>SignOnSanDiego.com >
    Warning issued on Cephalon painkiller | Philadelphia Inquirer | 09/27/2007

    My overall observations is that there are many factors influencing the pharma industry today and these are not likely to less anytime in the near future. It would be nice to see more positive articles but those seem to be hard to come by in the current environment.

    Technorati Tags: , , , , , , , ,


    Email Ed Vawter



    Related Posts:
  • IOM review of drug safety system could hurt FDA, industry
  • Your Vote on Nov 7 is Important
  • New Catalyzed Reaction and Tamiflu
  • About This Blog
  • New Shopping Site Become.com

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    October 3, 2007

    PDL up for sale

    by @ 12:20 pm.  Filed under Pharma News, Pharma

    Looks like PDL Biophrma after going through some tough times and laying-off people is finally up for sale. Here are just some of the articles recently.

    PDL to lay off 250, sell four drugs, shift focus - San Francisco Business Times
    PDL BioPharma up for sale - Examiner.com
    San Jose Mercury News - PDL for sale; CEO quits
    San Jose Mercury News - PDL BioPharma’s investors urge company’s sale, executive ousters

    This is case from my perspective of poor management which went on for quite a while until finally the major investors forced the ouster of the top two officers. Now it seems that the company’s only real option is to put themselves up for sale.

    This will be interesting to watch and I’m not sure how it will shake out. The latest rumors are that Roche may be interested in PDL, but they have refused to comment.

    Roche declines comment on PDL BioPharma deal rumours, analysts see …

    Other Resources

    News
    Yahoo! News Search Results for pdl biopharma
    pdl biopharma - Google News

    Blogs
    Google Blog Search: pdl biopharma
    Clusty Blogs » pdl biopharma
    pdl - IceRocket Blog Search
    pdl biopharma: Blogs, Photos, Videos and more on Technorati

    Technorati Tags:

    Email Ed Vawter



    Related Posts:
  • FDA Rejects Merck’s Arcoxia
  • VaxGen to Change After Anthrax Setback
  • Sanofi’s Acomplia Copied in India
  • Plan B Is Not Tobbacco
  • Watson and Andrex Merger

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Pages (999999): [1] 2 3 » ... Last »

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    May 2008
    S M T W T F S
    « Jan    
     123
    45678910
    11121314151617
    18192021222324
    25262728293031

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    76 queries. 1.927 seconds